- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04959240
Expanded Access to Velmanase Alfa
September 22, 2023 updated by: Chiesi Farmaceutici S.p.A.
Individual patient expanded access requests may be considered for patients who have no other treatment options.
Study Overview
Detailed Description
Expanded access may provide access for treatment prior to approval by the local regulatory agency.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
July 1, 2021
First Submitted That Met QC Criteria
July 1, 2021
First Posted (Actual)
July 13, 2021
Study Record Updates
Last Update Posted (Actual)
September 25, 2023
Last Update Submitted That Met QC Criteria
September 22, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Velmanase alfa-EAP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alpha-Mannosidosis
-
Zymenex A/SEuropean CommissionUnknown
-
Zymenex A/SEuropean CommissionCompleted
-
Zymenex A/SEuropean CommissionCompletedAlpha MannosidosisCzechia, Germany, Norway, United Kingdom
-
CENTOGENE GmbH RostockWithdrawnAlpha-Mannosidase B Deficiency | Lysosomal Alpha B Mannosidosis | Alpha-Mannosidase DeficiencyIndia, Sri Lanka, Germany
-
Chiesi Farmaceutici S.p.A.Completed
-
Zymenex A/SCompleted
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Zymenex A/SEuropean CommissionCompletedAlpha-MannosidosisBelgium, Denmark, Spain, United Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedAlpha-MannosidosisFrance
-
Zymenex A/SEuropean CommissionCompletedA Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-MannosidosisAlpha-MannosidosisDenmark, United Kingdom, France, Germany, Poland
Clinical Trials on Velmanase Alfa
-
Chiesi Farmaceutici S.p.A.RecruitingAlpha-MannosidosisUnited States
-
Chiesi Farmaceutici S.p.A.Withdrawn
-
Chiesi Farmaceutici S.p.A.CromsourceCompletedAlpha-MannosidosisFrance, Denmark, Austria, Germany, Italy
-
Jonsson Comprehensive Cancer CenterAmgenCompletedLymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant ConditionUnited States
-
Alexion Pharmaceuticals, Inc.Recruiting
-
ShireTakedaRecruiting
-
David L Rogers, MDActive, not recruitingNeuronal Ceroid Lipofuscinosis Type 2United States
-
ShireCompleted
-
SanofiPulse Infoframe Ltd.RecruitingNiemann-Pick Diseases | Acid Sphingomyelinase DeficiencyUnited States